Solventum stories
Begins trading on the New York Stock Exchange
On April 1, Solventum completed its spin-off from 3M and the newly independent healthcare company began trading on the New York Stock Exchange (NYSE) under the ticker symbol “SOLV.” By pioneering game-changing innovations at the intersection of health, material and data science, Solventum is advancing solutions that change patients’ lives for the better — while enabling healthcare professionals to perform at their best.
Today Solventum marks our first day as a publicly traded company and dedicated global healthcare leader. We’re a new company with a long legacy of creating breakthrough solutions that solve our customers’ toughest challenges. Solventum colleagues worldwide are united in our mission to enable better, smarter, safer healthcare to improve lives.
Bryan Hanson
Chief Executive Officer, Solventum
The Solventum business had sales of $8.2 billion in 2023 while part of 3M and is made up of 22,000 employees led by Bryan Hanson as chief executive officer, Wayde McMillan as chief financial officer and Carrie Cox as board chair.
“Solventum is now better positioned to create long-term value for shareholders through a greater focus on our core business, an enhanced ability to execute on industry-specific growth and market strategies and tailored capital allocation strategies,” said Hanson.
Solventum is a proven global leader in large, diverse and growing markets and is well positioned for success with a diverse portfolio of strong, trusted, reputable brands and deep innovation capabilities. Solventum solutions span across four business segments – Medical Surgical, Dental Solutions, Health Information Systems and Purification and Filtration. Solventum solutions are relied on everyday within the global healthcare industry, and ultimately contribute to higher-quality patient care, more efficient processes and workflow, and improved standards of safety and accuracy. For example, Solventum products have been used in over two billion dental restoration procedures worldwide, are estimated to treat 1.6 million hard-to-heal wounds annually, software solutions are used in many health systems worldwide — including over 75% of U.S. hospitals —and based on internal estimates, membrane technology is currently used annually in more than 25 million life-saving dialysis treatments. By listening to healthcare providers and patients, Solventum will continue to find new ways to achieve positive health outcomes and more efficient care.
Hanson and members of the Solventum Leadership Team will celebrate by ringing the Opening Bell at the NYSE on April 3.